iDose New Permanent J code
Date: July 10, 2024
In December 2023, the US Food and Drug Administration approved iDose TR for a single administration per eye intracameral implant that continuously releases travoprost, indicated for the reduction of intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
The Centers for Medicare and Medicaid Services has assigned a unique, permanent HCPCS J-code for iDose TR (Glaukos). The new level 2 J-code, J7355, was effective July 1, 2024.
In addition, CMS’s April 2024 update of the Hospital Outpatient Prospective Payment System included CPT codes that are intended to be used to cover the procedural component of iDose TR implantation, 0660T and 0661T.
These codes have been assigned to APC 5492 (Level 2 Intraocular Procedures), effective April 1, 2024.